German Market Access – Simplified
Everything you need to know in one place, explained in simple terms
Here are the G-BA decisions from the G-BA meeting held on 6 June 2024 on the early benefit assessments of Prevymis, Ebglyss, Takhzyro, Rubraca, Imfinzi, Brukinsa, and Praluent. Nearly all of them were negative! A complete database of all previous G-BA resolutions is available upon request. Prevymis (letermovir) CMV reactivation/disease, prophylaxis after stem cell transplantation;…
Here are the G-BA decisions from the G-BA meeting held on 16 May 2024 on the early benefit assessments of Darzalex, Kimmtrak, Voxzogo, Kaftrio+Kalydeco, Enhertu, Ryeqo, Epidyolex, and Onpattro. A complete database of all previous G-BA resolutions is available upon request. Darzalex (daratumumab); reassessment after expiry of previous resolution: multiple myeloma, first-line, ineligible for stem cell…
Here are the G-BA decisions from the G-BA meeting held on 2 May 2024 on the early benefit assessments of Akeega, Orserdu, Sogroya, Mounjuro, Rydapt, Olumiant, and Beovu. A complete database of all previous G-BA resolutions is available upon request. Akeega (niraparib/abiraterone acetate): prostate cancer, metastatic, castration-resistant, BRCA1/2 mutations, chemotherapy not clinically indicated, in combination with…
Here are the G-BA decisions from the G-BA meeting held on 4 April 2024 on the early benefit assessments of Tepkinly, and other decisions for Marstacimab, Blenrep, Pepaxti, and Evrysdi. A complete database of all previous G-BA resolutions is available upon request. Tepkinly (epcoritamab); diffuse large B-cell lymphoma, after ≥ 2 previous therapies – Orphan drug assessment,…
Here are the G-BA decisions from the G-BA meeting held on 15 February 2024 on the early benefit assessments of Trodelvy, Lonsurf, Voxzogo, Kymriah, Tecvayli, Refixia, and Galafold. A complete database of all previous G-BA resolutions is available upon request. Trodelvy (sacituzumab govitecan); new indication: breast cancer, HR+, HER2-, at least 3 previous therapies – Indication of…
Here are the G-BA decisions from the G-BA meeting held on 1 February 2024 on the early benefit assessments of Camzyos, Sirturo, Columvi, Opdivo, Pombiliti, Jardiance, Xydalba, and Alprolix. A complete database of all previous G-BA resolutions is available through my membership. Camzyos (mavacamten); symptomatic hypertrophic obstructive cardiomyopathy (NYHA class II-III) – Hint of considerable additional benefit…
Here are the G-BA decisions from the G-BA meeting held on 21 December 2023 on the early benefit assessments of Yescarta, Bimzelx, Adempas, Koselugo, and Opdivo. A complete database of all previous G-BA resolutions is available through my membership. Yescarta (axicabtagene ciloleucel); re-assessment of an orphan drug after exceeding the €30mn threshold: diffuse large B-cell lymphoma…
Here are the G-BA decisions from the G-BA meeting held on 7 December 2023 on the early benefit assessments of Entresto, Cosentyx, and Ultomiris. A complete database of all previous G-BA resolutions is available through my membership. Entresto (sacubitril/valsartan); new indication: chronic heart failure with left ventricular dysfunction, patients aged 1 year to 17 years – Additional…
Here are the G-BA decisions from the G-BA meeting held on 16 November 2023 on the early benefit assessments of Breyanzi and Tecartus. A complete database of all previous G-BA resolutions is available through my membership. Breyanzi (lisocabtagene maraleucel); new indication: Diffuse large B-cell lymphoma, high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma and follicular lymphoma…
Here are the G-BA decisions from the G-BA meeting held on 2 November 2023 on the early benefit assessments of Zynlonta, Imcivree, Evusheld, and Reblozyl. A complete database of all previous G-BA resolutions is available through my membership. Zynlonta (loncastuximab tesirine): diffuse large B-cell lymphoma and high-grade B-cell lymphoma, after ≥ 2 prior therapies – Additional benefit…